Inhibition of Leishmania major pteridine reductase by 2,4,6- triaminoquinazoline: Structure of the NADPH ternary complex

32Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The structure of Leishmania major pteridine reductase (PTR1) in complex with NADPH and the inhibitor 2,4,6-triaminoquinazoline (TAQ) has been solved in a new crystal form by molecular replacement and refined to 2.6 Å resolution. The inhibitor mimics a fragment, the pterin head group, of the archetypal antifolate drug methotrexate (MTX) and exploits similar chemical features to bind in the PTR1 active site. Despite being a much smaller molecule, TAQ displays a similar inhibition constant to that of MTX. PTR1 is a target for the development of improved therapies for infections caused by trypanosomatid parasites and this analysis provides information to assist the structure-based development of novel enzyme inhibitors. © 2004 International Union of Crystallography.

Cite

CITATION STYLE

APA

McLuskey, K., Gibellini, F., Carvalho, P., Avery, M. A., & Hunter, W. N. (2004). Inhibition of Leishmania major pteridine reductase by 2,4,6- triaminoquinazoline: Structure of the NADPH ternary complex. Acta Crystallographica Section D: Biological Crystallography, 60(10), 1780–1785. https://doi.org/10.1107/S0907444904018955

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free